Since coumarin and thiazole derivatives are known to have antioxidant properties, a novel derivative was synthesized in this article. 3‐(2‐((4‐(trifluoromethyl)phenyl)amino)thiazol‐4‐yl)‐2H‐chromen‐2‐one (ATC) was synthesized as a novel compound with high yield and characterized by Raman, FT‐IR, 13C‐NMR, and 1H‐NMR spectroscopic procedures and DFT calculations. In this study, the potential in vitro antiproliferative properties of the ATC compound were evaluated on colorectal cancer (HT29) and melanoma (SK‐MEL‐30) cell lines. According to the results, the compound was found to be significantly active, approximately 2.6‐fold, against melanoma cells compared to healthy fibroblast (L929) cells. Unlike melanoma cells, the compound did not have any adverse effects on colorectal cancer cells. Due to these findings, the compound can be harnessed as a promising antiproliferative drug candidate for preclinical studies against melanoma.